

Shikai Geng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8287940/publications.pdf>

Version: 2024-02-01

9
papers

185
citations

1683934
5
h-index

1588896
8
g-index

9
all docs

9
docs citations

9
times ranked

167
citing authors

#	ARTICLE	IF	CITATIONS
1	Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis. Clinical and Experimental Rheumatology, 2021, , .	0.4	2
2	Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials. Lupus Science and Medicine, 2020, 7, e000429.	1.1	26
3	Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. Clinical Rheumatology, 2020, 39, 3099-3104.	1.0	8
4	Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatology, The, 2020, 2, e210-e216.	2.2	36
5	<p>Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World</p>. Journal of Inflammation Research, 2020, Volume 13, 1141-1150.	1.6	6
6	Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. BMC Health Services Research, 2019, 19, 378.	0.9	21
7	Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China. International Journal of Clinical Pharmacy, 2019, 41, 1247-1255.	1.0	4
8	Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram. Patient Preference and Adherence, 2018, Volume 12, 1757-1765.	0.8	78
9	Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis. Clinical and Experimental Rheumatology, 0, , .	0.4	4